AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04847232
Drug: Sodium Zirconium Cyclosilicate (SZC)
DrugBank: Sodium zirconium cyclosilicate (DB14048)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Powder for oral suspension in a sachet. A dose is titrated in 5 g increments during a period of 4 weeks from 5 g up to 15 g qd on non-dialysis days. Afterward, the dose is adjusted monthly (or more frequent based on clinical judgment) depending on the current potassium value as measured after the long interdialytic interval (LIDI).
Trial: NCT01063933
Drug: Peramivir
RxNorm normalized name: Peramivir
DrugBank: Peramivir (DB06614)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Peramivir is a liquid for parenteral administration. Cohort I: Peramivir, 10 mg/kg intravenously (IV) every day (QD) (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Cohort II: Peramivir 12 mg/kg IV QD (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Cohort III: Peramivir 16 mg/kg QD (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Proposed doses for subjects in Cohorts IV, V, VI, and VII are 18, 18, 14 and 12 mg/kg, respectively, IV, QD for 5 days or until hospital discharge, whichever comes first. IV peramivir will be administered over 60 minutes.
Trial: NCT05031078
Drug: Lidocaine injections
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-2% lidocaine injections.~1% lidocaine, an FDA approved local anesthetic, will be injected subcutaneously to numb the area of the lymph node being sampled; whereas 1-2% lidocaine will be injected into the tissue surrounding the area where the bone marrow will be removed. In adults the recommended dose is 7 mg/kg with a maximum of 500 mg.
Trial: NCT06539494
Drug: Omeprazole 40 MG
RxNorm normalized name: omeprazole 40 MG
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor twice a day for 4 weeks
Trial: NCT05949658
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5mg, 10mg, or 15mg once weekly sirolimus
Trial: NCT05949658
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5mg, 10mg, or 15mg once weekly everolimus
Trial: NCT05285917
Drug: Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea has a narrow therapeutic window such that selection of the correct dose is essential to optimize benefits and avoid toxicity.
Trial: NCT05401097
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV or SC
Trial: NCT05401097
Drug: Enasidenib
RxNorm normalized name: Enasidenib
DrugBank: Enasidenib (DB13874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05401097
Drug: Ivosidenib
RxNorm normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05401097
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT06291064
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirubicin is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Cyclophosphamide.
Trial: NCT06291064
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Carboplatin. Dosing will start after treatment with Epirubicin and Cyclophosphamide (EC) is completed.
Trial: NCT06291064
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Docetaxel. Dosing will start after treatment with EC is completed.
Trial: NCT04747496
Drug: Edoxaban
RxNorm normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This is a non-interventional, observational study.
Trial: NCT06470763
Drug: ANV600 + pembrolizumab (KEYTRUDA®)
RxNorm normalized name: pembrolizumab Injection [Keytruda]
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ANV600 administered by intravenous (IV) infusion pembrolizumab (KEYTRUDA®) administered by intravenous (IV) infusion
Trial: NCT04606069
Drug: Regadenoson
RxNorm normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regadenoson will be given intravenously as 5 ug/kg (up to 400 mg/patient) loading dose over 30 mins (to avoid unpleasant side effects sometimes associated with the rapid bolus injection of Regadenoson), followed by a continuous slow infusion (1.44micrograms/kg/hour) with the use of a pediatric infusion pump for 6 hours.
Trial: NCT05513001
Drug: LOU064 (open label)
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOU064 (open-label) active treatment
Trial: NCT06540833
Drug: ITI-1284
RxNorm normalized name: Arthur Itis
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ITI-1284 10 mg or 20 mg rapidly disintegrating tablet, taken once daily, sublingual administration
Trial: NCT05176951
Drug: Treprostinil Palmitil
RxNorm normalized name: Treprostinil palmitil
DrugBank: Treprostinil palmitil (DB18792)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral inhalation using a capsule-based dry powder inhaler device.
Trial: NCT05148286
Drug: Treatment
RxNorm normalized name: Acne Treatment
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the treatment group, 200cc of 20% human albumin with 15 cc per kg of crystalloid will be administered over 1\~2h for initial fluid resuscitation. The treating physicians can choose the type of fluid, such as balanced fluid or isotonic saline.
Trial: NCT06419803
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin will be used in gestational diabetics to control blood glucose levels
Trial: NCT06702202
Drug: 0.5% hyperbaric bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given in Subarachnoid block group (Group S)
Trial: NCT05075980
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05920980
Drug: lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the lidocaine groups, lidocaine 1.5mg/kg/h was continuously infused (using ideal body weight) during the whole procedure, postoperative analgesia pump with lidocaine (lidocaine 50mg/kg, sufentanil 2ug/kg, glassetron 12mg), diluted to 200ml with saline until 72h after surgery. Blood samples will be collected from some patients in the lidocaine group for the measurement of lidocaine plasma concentration.
Trial: NCT05887609
Drug: Mirvetuximab Soravtansine
RxNorm normalized name: MIRVETUXIMAB SORAVTANSINE
DrugBank: Mirvetuximab soravtansine (DB12489)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: is an antibody-drug conjugate (ADC) that consists of a high affinity humanized monoclonal antibody against folate receptor α (FRα, the protein product of the folate receptor 1 \[FOLR1\] gene) that is conjugated to a cytotoxic maytansinoid by the hindered disulfide succinimidyl 4-(pyridine-2-yl)disulfanyl)-2-sulfo-butyrate linker (sulfo-SPDB).
Trial: NCT05887609
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular functions, such as DNA transcription and DNA repair.
Trial: NCT05199480
Drug: Tobacco flavored liquid type 1
RxNorm normalized name: Tobacco
DrugBank: Tobacco leaf (DB10710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A commercially available cartridge-based device with tobacco flavored liquid.
Trial: NCT05199480
Drug: Tobacco flavored liquid type 2
RxNorm normalized name: Tobacco
DrugBank: Tobacco leaf (DB10710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A commercially available cartridge-based device with tobacco flavored liquid.
Trial: NCT05443009
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A buccal infiltration injection followed by palatal injections and interpapillary injections of 2% lidocaine with 1:100,000 epinephrine will be administered.
Trial: NCT05443009
Drug: Articaine
RxNorm normalized name: Articaine
DrugBank: Articaine (DB09009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered.
Trial: NCT06156579
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine 20 mg/m\^2, i.v., once daily, 10 days
Trial: NCT06156579
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax, 400 mg, p.o., once daily, 28 days
Trial: NCT06612255
Drug: Delafloxacin
RxNorm normalized name: Delafloxacin
DrugBank: Delafloxacin (DB11943)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Delafloxacin tablet
Trial: NCT06612255
Drug: Delafloxacin Powder
DrugBank: Delafloxacin (DB11943)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Delafloxacin powder for oral suspension formulation
Trial: NCT05111626
Drug: Bemarituzumab
RxNorm normalized name: Bemarituzumab
DrugBank: Bemarituzumab (DB16105)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bemarituzumab will be administered as intravenous (IV) infusion.
Trial: NCT05111626
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab will be administered as IV infusion.
Trial: NCT03433807
Drug: Idebenone
RxNorm normalized name: Idebenone
DrugBank: Idebenone (DB09081)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: 900 mg idebenone/day (2 tablets to be taken 3 times a day with meals)
Trial: NCT04728633
Drug: Carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given via infusion
Trial: NCT04728633
Drug: Ethiodized Oil
RxNorm normalized name: ethiodized oil
DrugBank: Ethiodized oil (DB00965)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given via infusion
Trial: NCT05023980
Drug: Pirtobrutinib
RxNorm normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT05023980
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT05023980
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV
Trial: NCT06764095
Drug: Enfortumab Vedotin
RxNorm normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06555744
Drug: ZW191
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered intravenously
Trial: NCT06209606
Drug: Ruxolitinib Oral Tablet [Jakafi]
RxNorm normalized name: ruxolitinib Oral Tablet [Jakafi]
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib will be administered on days 1-28 of the treatment cycle.
Trial: NCT06209606
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide will be administered on Days 1-21 of the treatment cycle.
Trial: NCT06209606
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyl-prednisolone will be administered on Days 1-28 of the treatment cycle.
Trial: NCT05430009
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg every 3 weeks or 400 mg every 6 weeks
Trial: NCT06495125
Drug: Avutometinib
RxNorm normalized name: Avutometinib
DrugBank: Avutometinib (DB15254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06495125
Drug: Defactinib
RxNorm normalized name: Defactinib
DrugBank: Defactinib (DB12282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06132035
Drug: CG-P5 peptide
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will instill daily 1 package of CG-P5 peptide eye drops in the study eye \[self-administered\] using the single use tear-off disposable packaging
Trial: NCT06132035
Drug: Aflibercept Injection [Eylea]
RxNorm normalized name: aflibercept Injection [Eylea]
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patient will receiver Eylea® (Aflibercept) intravitreal injection once in a month
Trial: NCT05594290
Drug: Retifanlimab
RxNorm normalized name: Retifanlimab
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retifanlimab i.v. 500 mg day 1
Trial: NCT05594290
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 25 mg/sqm i.v. day 1, 2 (recommended platinum agent) or carboplatin AUC 4 i.v., day 1 (in patients unsuited or unfit for cisplatin)
Trial: NCT05594290
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide 100 mg/sqm iv. day 1, 2, 3
Trial: NCT04431999
Drug: Whole blood transfusion
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe trauma patients with a life threatening bleeding will be managed with 3 whole blood bags for the 1st and 2nd pack. The later packs will consist of 3 packed red blood cells (PRBCs), 3 plasma units and 1 dose of platelets.
Trial: NCT05214599
Drug: Budesonide Gel
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Twice daily regimen
Trial: NCT06008691
Drug: novel MAB (alone or in combination)
RxNorm normalized name: B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
DrugBank: Elranatamab (DB15395)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: novel MAB (alone or in combination) based on presence of an EMA clinical indication since 2020 and prescribed according to the indications for use authorized for marketing in Italy
Trial: NCT04484818
Drug: Darolutamide
RxNorm normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT04484818
Drug: Goserelin Acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given via injection
Trial: NCT04484818
Drug: Leuprolide Acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04484818
Drug: Triptorelin
RxNorm normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given via injection
Trial: NCT04818632
Drug: AZD9833 with palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Part B: AZD9833 with palbociclib dose expansion
Trial: NCT04818632
Drug: AZD9833 with everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Part B: AZD9833 with everolimus dose expansion
Trial: NCT06566794
Drug: Bupropion Hydrochloride Capsels
RxNorm normalized name: Bupropion Hydrochloride
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 20 mg tablet.
Trial: NCT06566794
Drug: Repaglinide Capsels
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 0,05 mg tablet.
Trial: NCT06566794
Drug: Omeprazole 10 MG
RxNorm normalized name: omeprazole 10 MG
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 10 mg tablet.
Trial: NCT06566794
Drug: Dextromethorphan Oral Solution
RxNorm normalized name: dextromethorphan Oral Solution
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5,0 ml of 2 mg/ml oral solution (10 mg dextromethorphan).
Trial: NCT06566794
Drug: Midazolam oral solution
RxNorm normalized name: midazolam Oral Solution
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0,5 ml of 2 mg/ml oral solution (1,0 mg midazolam).
Trial: NCT06566794
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 x 25 mg tablets
Trial: NCT06014658
Drug: Antibody-Drug Conjugate
RxNorm normalized name: antibody-drug conjugate DP303c
DrugBank: DP-303c (DB17212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBRC-101: AN ANTI-EPHA5 MONOMETHYL AURISTATIN E (MMAE) ANTIBODY DRUG CONJUGATE
Trial: NCT05757973
Drug: Talquetamab
RxNorm normalized name: Talquetamab
DrugBank: Talquetamab (DB16678)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talquetamab will be administered subcutaneously.
Trial: NCT05806671
Drug: Dalpiciclib
RxNorm normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalpiciclib 125 mg/day orally continuously dosed for 3 weeks followed by 1 week off
Trial: NCT05806671
Drug: Pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib 320mg/day orally continuously
Trial: NCT05806671
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant 500mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle
Trial: NCT05269706
Drug: Cannabidiol 200mg
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol 200mg (twice daily)
Trial: NCT05269706
Drug: Epidiolex
RxNorm normalized name: Epidiolex
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Epidiolex 400mg (twice daily)
Trial: NCT05269706
Drug: Cannabidiol 400mg
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol 400mg (twice daily)
Trial: NCT06540599
Drug: Analgesic
RxNorm normalized name: Analgesic
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: comparing the effectiveness of analgesics in endometrial biopsy
Trial: NCT05630001
Drug: Iptacopan
RxNorm normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with iptacopan at a dose of 200 mg b.i.d. will start on the first day (Day 1) and continue for 24 weeks.
Trial: NCT06254391
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implementation of low-dose aspirin (30 mg)
Trial: NCT04838405
Drug: CT-388
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic Peptide
Trial: NCT05705596
Drug: Hesperetin
RxNorm normalized name: HESPERETIN
DrugBank: Hesperetin (DB01094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: increases sweetness of 7% sucrose solution to match sweetness of 10% sucrose solution
Trial: NCT06174922
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SUBA-itraconazole for 4 months
Trial: NCT06288373
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab is administered at 200mg, q3w (second and third cycles) before radical surgery
Trial: NCT06288373
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin：75-80mg/m2, D1-D2，q3w (3 cycles)，intravenous infusion, administered at a rate of 1mg/min.
Trial: NCT06288373
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab paclitaxel: 260 mg/m2，D1，q3w （3 cycles），intravenous infusion, administered over 30min.
Trial: NCT05014776
Drug: Tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Tadalafil (20 mg) will be administered orally every day on days 3-21 for cycles 1-6.
Trial: NCT05014776
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Pembrolizumab (200 mg) will be administered IV on Day 1 of cycles 1-6.
Trial: NCT05014776
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Ipilimumab (50mg) will be administered IV on Day 1 of Cycles 1, 3, and 5.